Business Wire

TX-FLUENCE

2.9.2021 14:02:06 CEST | Business Wire | Press release

Share
Fluence by OSRAM Implements LED Lighting into HortiPolaris’s Cultivation and Research Facility

Fluence by OSRAM (Fluence), a leading global provider of energy-efficient LED lighting solutions for commercial cannabis and food production, and HortiPolaris, a Beijing, China-based greenhouse producing 20 varieties of tomatoes and eight types of lettuce, announced the implementation of Fluence LED lighting solutions into HortiPolaris’s cultivation and research facility.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210902005266/en/

HortiPolaris is a science and technology leader in the region, standing on the cutting edge of farming and education in booming Beijing where the population and demand for fresh, quality produce continues to grow. Its state-of-the-art greenhouse—inspired by the founder’s work in the Netherlands—represents the future of controlled environment agriculture, housing 2,000 square meters of lettuce and 22,850 square meters of tomatoes. HortiPolaris originally equipped its farm with HPS lighting, but found energy costs were too high for a market that valued quality over yield, prompting the company to switch to LED lighting systems that provide crop consistency, energy efficiency and seasonal cultivation flexibility for growers.

“We can use LEDs not only in the winter period, but also in the spring, autumn and even summer to increase yield and stabilize quality,” said Dan Xu, founder and general manager of HortiPolaris. “We are carrying out trials together with Fluence to figure out the best combination of light intensity and light spectrum in order to increase the neutral level to maximize margin and to differentiate ourselves in the market.”

HortiPolaris distributes a variety of popular tomato and lettuce cultivars to local and regional markets and leverages Fluence’s broad-spectrum VYPR LED lighting solutions in its greenhouse and Fluence’s RAZR LED solutions in HortiPolaris’s vertical propagation racks.

“Transitioning from HPS lighting to Fluence LED solutions affords growers a way to improve the quality of their produce such as color and consistency—critical factors shoppers in the growing Beijing region are prioritizing,” said David Cohen, CEO of Fluence. “We are proud to partner with HortiPolaris, an innovator and evolved horticulture leader in the rapidly expanding Chinese market, that recognizes the advantages of LED technology developmentally for crops’ growing cycles and also operationally in facility design.”

Applying Fluence’s LED lighting solutions provides growers better control over plants’ external variables such as temperature and humidity, eliminating once-crucial concerns about overheating as a result of growing under HPS lighting.

“There are several advantages to Fluence lighting solutions,” said Yuchong Chen, technical assistant at HortiPolaris. “Not only can they provide maximum light intensity, but they also allow us to control intensity for different growing stages. Additionally, the uniform light the RAZR fixtures provide is quite important for grafting. That’s why we use Fluence LED lighting solutions in all seasons to increase yield and stabilize the quality of our grow.”

Fluence’s partnership with HortiPolaris bolsters the farm’s ability to harvest quality produce and supply the market year-round. The companies’ ongoing trials to discover optimum lighting strategies for unique cultivation environments are charting the course for the future of innovative food production that will ultimately help the world grow smarter.

To learn more about Fluence, its customers and the company’s ongoing research, visit www.fluence.science/case-studies .

About Fluence by OSRAM

Fluence Bioengineering, Inc., a wholly-owned subsidiary of OSRAM , creates powerful and energy-efficient LED lighting solutions for commercial crop production and research applications. Fluence is a leading LED lighting supplier in the global cannabis market and is committed to enabling more efficient crop production with the world’s top vertical farms and greenhouse produce growers. Fluence global headquarters are based in Austin, Texas, with its EMEA headquarters in Rotterdam, Netherlands. For more information about Fluence, visit www.fluence.science .

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

SOLUM and Simbe Expand European Collaboration to Advance Intelligent Store Operations5.3.2026 08:00:00 CET | Press release

SOLUM (KOSPI: 248070) and Simbe announced the expansion of their strategic collaboration to further integrate autonomous store intelligence with SOLUM’s Newton Electronic Shelf Label (ESL) infrastructure across Europe. The collaboration was highlighted at EuroShop, where Simbe’s Store Intelligence™ platform was demonstrated live at the SOLUM booth. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260304620371/en/ SOLUM and Simbe announced the expansion of their strategic collaboration to further integrate autonomous store intelligence with SOLUM’s Newton Electronic Shelf Label (ESL) infrastructure across Europe. (Image: SOLUM) Simbe recently introduced Tally 4.0, the next generation of their autonomous shelf-scanning robot, reflecting the company’s continued evolution in retail shelf digitization, incorporating extended runtime, enhanced edge computing, and advanced vision capabilities. Designed to deliver deeper shelf coverag

Mosaic Clinical Technologies Announces FDA Breakthrough Device Designation for Cognita’s Generative AI Model for Radiology5.3.2026 08:00:00 CET | Press release

Breakthrough designation means Cognita™ will engage in prioritized interaction with FDA regarding clearance of device designed to help solve the radiology capacity bottleneck Mosaic Clinical Technologies™, a wholly-owned subsidiary of Radiology Partners, is pleased to announce that Cognita™, its AI business unit developing generative vision-language models (VLMs) for radiology, has received U.S. Food and Drug Administration (FDA) Breakthrough Device Designation for Cognita Chest X-Ray (CXR)™1 across multiple critical indications. Cognita CXR is an industry-first generative vision-language model designed to assist radiologists in the interpretation of chest X-rays and is the first radiology generative AI model, and one of very few radiology AI solutions, to be granted this designation2. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260304633206/en/ Cognita™ operates as the AI business unit of Mosaic Clinical Technologies™, a

Cielo Advances Resilient Remote Connectivity for Its Nationwide Payment Terminal Fleet With Thales5.3.2026 08:00:00 CET | Press release

Cielo, one of Brazil’s leading payment service providers, is piloting remote connectivity management for its point-of-sale (POS) terminals across the country, in partnership with Thales. By deploying Thales’s eSIM connectivity management platform based on the latest GSMA SGP.32 IoT standard, Cielo is accelerating its transition from manual, on-site SIM management to fully remote, secure and resilient connectivity. For Cielo, connectivity is mission critical. When payment terminals lose network access, transactions stop. To strengthen operational resilience and enhance merchant experience, Cielo is modernizing its connectivity architecture across its terminal fleet. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260304089321/en/ Cielo advances resilient remote connectivity for its nationwide payment terminal fleet with Thales. Using Thales’s eSIM technology as part of this strategy, Cielo can remotely switch mobile network op

GAIA and Daiichi Sankyo Europe Enter Exclusive Partnership to Launch Next-Generation Digital Therapeutic for Cardiovascular Care in Europe.5.3.2026 08:00:00 CET | Press release

GAIA, the pioneer in evidence-based digital therapeutics and Daiichi Sankyo Europe, today announced an exclusive strategic partnership to commercialize lipodia upon regulatory approval1. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260224658973/en/ Dr. Mario Weiss, Founder & CEO of GAIA AG This digital therapeutic is designed to support adults living with hypercholesterolemia. The comprehensive collaboration brings together GAIA’s long-standing expertise in developing clinically validated non-pharmacological interventions with Daiichi Sankyo’s highly scientific experience in cardiovascular risk management and health. Together, the partners - both members of the German Association of Research-Based Pharmaceutical Companies (vfa) - aim to address a persistent gap in chronic care: leveraging digital technologies to make a difference in patients’ lives by supporting sustainable, long-term behaviour change. Expanding Cardiovasc

Galderma Delivers Record 2025 Results With Net Sales of 5.207 Billion USD, up 17.7% at Constant Currency1, and Core EBITDA2 of 1.211 billion USD, Growing 18.9% at Constant Currency5.3.2026 07:00:00 CET | Press release

Ad hoc announcement pursuant to Art. 53 LR Galderma Group AG (SIX:GALD), the pure-play dermatology category leader, today announced its financial results for the full year 2025. Record net sales of 5,207 million USD, surpassing 5 billion USD in a year for the first time and representing 17.7% year-on-year growth on a constant currency1 basis, primarily driven by volume. Broad-based net sales growth, growing double-digits in both International markets and the U.S. Outperforming the market in each product category, with strong net sales growth in Injectable Aesthetics (11.5%), Dermatological Skincare (9.3%) and Therapeutic Dermatology (50.2%), all year-on-year at constant currency. Strong launch momentum across future growth drivers, including Nemluvio® (nemolizumab) delivering 452 million USD in net sales; Relfydess™ (RelabotulinumtoxinA) outperforming expectations in 17 International markets; Sculptra® gaining significant market share in its first year in China; and continued new produ

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye